HilleVax, Inc. and XOMA Royalty Corporation have announced a definitive merger agreement, under which XOMA Royalty will acquire all outstanding shares of HilleVax common stock. The transaction involves a cash payment of $1.95 per share plus a contingent value right. The tender offer to acquire HilleVax shares is expected to commence by August 18, 2025, with the acquisition anticipated to close in September 2025. Approximately 22.9% of HilleVax shareholders, including certain officers, directors, and stockholders, have agreed to support the merger by tendering their shares. The announcement was made by both companies, with Leerink Partners and Latham & Watkins LLP advising HilleVax, and Gibson, Dunn & Crutcher LLP advising XOMA Royalty.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.